OncoMatch/Clinical Trials/NCT06235697
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Is NCT06235697 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies ADT for prostate cancer.
Treatment: ADT — This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT2B, CT2C, CT3A, CT3B (NCCN classification guidelines (Version 4.2022 - May 10, 2022))
Grade: Gleason 7 (grade group 2 or 3)Gleason 4+3 (grade group 3)Gleason 8-10 (grade group 4 or 5)Primary Gleason pattern 5 (Gleason/grade group)
Participants with unfavourable risk prostate cancer are eligible according to the following NCCN classification guidelines (Version 4.2022 - May 10, 2022): • Unfavourable-intermediate risk - has one or more of the following: * 2 or 3 Intermediate Risk Factors (IRFs): cT2b-cT2c, Gleason 7 (grade group 2 or 3), and/or PSA 10-20 ng/ml; * Gleason 4+3 (grade group 3) * > 50% biopsy cores positive • High risk - has one of the following: * cT3a * Gleason 8-10 (grade group 4 or 5) * PSA > 20 ng/ml • Very-high risk - has at least one of the following: * cT3b-cT4 * Primary Gleason pattern 5 * 2 or 3 high risk features: cT3a, Gleason 8-10 (grade group 4 or 5), and/or PSA > 20 ng/ml * > 4 cores with Gleason 8-10 (grade group 4 or 5)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: pelvic radiotherapy
Prior pelvic radiotherapy
Cannot have received: chemotherapy
Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
Cannot have received: PARP inhibitor
Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
Cannot have received: radioligand
Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
Cannot have received: investigational drug
Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
Cannot have received: ablative therapy to the prostate (cryotherapy, HIFU, TULSA, focal laser ablation, photodynamic therapy)
any ablative therapy to the prostate (cryotherapy, HIFU, TULSA, focal laser ablation, photodynamic therapy)
Cannot have received: prostatectomy (simple prostatectomy, radical prostatectomy)
prostatectomy (simple or radical)
Cannot have received: transurethral resection of the prostate (TURP)
transurethral resection of the prostate (TURP)
Cannot have received: steam vaporization (Rezum)
Prior steam vaporization (Rezum)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Kaiser Permanente-Deer Valley Medical Center · Antioch, California
- Kaiser Permanente Dublin · Dublin, California
- Kaiser Permanente-Fremont · Fremont, California
- Kaiser Permanente Fresno Orchard Plaza · Fresno, California
- Kaiser Permanente-Fresno · Fresno, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06235697 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiotherapy, chemotherapy, PARP inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage CT2B or CT2C or CT3A or CT3B is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages